<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11863015</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1593</article-id><article-id pub-id-type="other">EPP0274</article-id><article-id pub-id-type="pii">S0924933824015931</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Short-chain fatty acids in schizophrenia: are they affected by a depressive state?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Couce-S&#x000e1;nchez</surname><given-names>M.</given-names></name><xref rid="aff3763" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1586" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Paniagua</surname><given-names>G.</given-names></name><xref rid="aff3763" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3764" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez-Blanco</surname><given-names>L.</given-names></name><xref rid="aff3763" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3764" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3765" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff3766" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a-Fern&#x000e1;ndez</surname><given-names>A.</given-names></name><xref rid="aff3764" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;nez-Cao</surname><given-names>C.</given-names></name><xref rid="aff3764" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sabater</surname><given-names>C.</given-names></name><xref rid="aff3766" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Margolles</surname><given-names>A.</given-names></name><xref rid="aff3766" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bobes</surname><given-names>J.</given-names></name><xref rid="aff3764" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3765" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff3766" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a-Portilla</surname><given-names>M. P.</given-names></name><xref rid="aff3763" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3764" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3765" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff3766" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;iz</surname><given-names>P.</given-names></name><xref rid="aff3763" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff3764" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3765" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff3766" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="aff3763"><sup>1</sup>AGC Salud Mental IV, SESPA</aff><aff id="aff3764"><sup>2</sup>Psychiatry, <institution>University of Oviedo</institution></aff><aff id="aff3765"><sup>3</sup>G05, CIBERSAM</aff><aff id="aff3766"><sup>4</sup>ISPA, <city>Oviedo</city>, <country>Spain</country></aff><author-notes><corresp id="cor1586"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1568">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S765</fpage><lpage>S766</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824015931a.pdf"/><abstract><sec id="sec9533"><title>Introduction</title><p>Short-chain fatty acids (SCFA) are bacterial metabolites that, within microbiome-gut-brain axis, make a promising research line on etiopathology of mental diseases like schizophrenia (SZ) and major depression disorder. Besides, depressive symptoms are frequent clinical features of SZ.</p></sec><sec id="sec9534"><title>Objectives</title><p>
<list list-type="bullet"><list-item><p>Describe fecal SCFA concentrations in SZ patients.</p></list-item><list-item><p>Analyze differences in SCFA depending on:</p></list-item><list-item><p>Depression.</p></list-item><list-item><p>
Clinical severity, antipsychotics and antidepressants, comorbidities (pro-inflammatory state/obesity/metabolic syndrome [MetS]), lifestyle.
</p></list-item></list></p></sec><sec id="sec9535"><title>Methods</title><p>Cross-sectional study of 67 outpatients [mean age=43.52&#x000b1;12.42, range=22-67; males=40 (59.7%)] with diagnosis (DSM-5) of SZ recruited from their mental health clinics in Oviedo (Spain).
<list list-type="bullet"><list-item><p>Assessment:</p></list-item><list-item><p>Fecal SCFA (gas chromatography;&#x003bc;g/mL).</p></list-item><list-item><p>Plasmatic C-reactive protein (CPR;mg/dL).</p></list-item><list-item><p>PANSS, Calgary Depression (CDS), International Physical Activity (IPAQ), Mediterranean Diet Adherence (MEDAS).</p></list-item><list-item><p>Toxic habits (alcohol use/smoking/cannabis).</p></list-item><list-item><p>Chlorpromazine equivalent doses (CPZ-ED), use of antidepressants.</p></list-item><list-item><p>MetS (ATP-III), body mass index (BMI; kg/cm2).</p></list-item><list-item><p>Statistics: Spearman correlation, U Mann-Whitney, ANCOVA.
</p></list-item></list></p></sec><sec id="sec9536"><title>Results</title><p>14 patients showed clinical depression (CDS&#x02265;5). There were no differences in age or sex between groups. 36 patients (53.7%) showed systemic low-grade inflammation (CPR&#x02265;0.3mg/dL) and 32 (30.8%) MetS.Table 1 shows fecal SCFA levels by depressive state. Means (SD) are ahown.<table-wrap position="anchor" id="tab43"><label>
Table 1</label><alternatives><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/><col align="left" width="1*" span="1"/></colgroup><thead><tr><th rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">CDS&#x02264;4</th><th align="center" valign="middle" rowspan="1" colspan="1">CDS&#x02265;5</th><th align="center" valign="middle" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" rowspan="1" colspan="1">U Mann-Whitney
<break/>(p-value)</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Acetate</td><td align="center" valign="middle" rowspan="1" colspan="1">21.449(12.823)</td><td align="center" valign="middle" rowspan="1" colspan="1">12.911(7.189)</td><td align="center" valign="middle" rowspan="1" colspan="1">19.665(12.328)</td><td align="center" valign="middle" rowspan="1" colspan="1">221.000(0.021)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Propanoate</td><td align="center" valign="middle" rowspan="1" colspan="1">9.170(6.819)</td><td align="center" valign="middle" rowspan="1" colspan="1">6.848(6.036)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.685(6.687)</td><td align="center" valign="middle" rowspan="1" colspan="1">268.500(0.114)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Butyrate</td><td align="center" valign="middle" rowspan="1" colspan="1">8.529(6.436)</td><td align="center" valign="middle" rowspan="1" colspan="1">7.875(8.232)</td><td align="center" valign="middle" rowspan="1" colspan="1">8.392(6.787)</td><td align="center" valign="middle" rowspan="1" colspan="1">320.000(0.432)</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Total SCFA</td><td align="center" valign="middle" rowspan="1" colspan="1">39.148(23.770)</td><td align="center" valign="middle" rowspan="1" colspan="1">31.415(24.526)</td><td align="center" valign="middle" rowspan="1" colspan="1">36.742(23.549)</td><td align="center" valign="middle" rowspan="1" colspan="1">250.000(0.062)</td></tr></tbody></table><graphic xlink:href="S0924933824015931-TABU0043" position="anchor"/></alternatives></table-wrap>
</p><p>Correlations were found in Age with Butyrate (r=-0.248,p=0.043) and weekly alcohol units with Propanoate (r=0.250,p=0.041) plus trend to significance with Butyrate (r=0.232,p=0.059). It also showed a trend towards statistical relation for CPZ-ED with Propanoate (r=-0.253,p=0.039) and Total SCFA (r=-0.253,p=0.039). We found no correlation in SCFA with MetS, CGI, PANSS-N, BMI, IPAQ, MEDAS and other toxic habits.</p><p>ANCOVA was performed to Acetate and Total SCFA using depression state as independent variable and Age and CPZ-ED as covariates. There was a trend towards statistical significance for Acetate (F=3.937,p=0.052,&#x003b7;2=0.059) whereas Total SCFA showed no difference (F=1.350,p=2.250,&#x003b7;2=0.021).</p></sec><sec id="sec9537"><title>Conclusions</title><p>
There seems to be lower levels of fecal Acetate in SZ patients with depressive symptoms, considering age and antipsychotic intake. In our sample there was no relation between SFCA and clinical severity, lifestyle, comorbidities or antidepressant use.</p></sec><sec id="sec9538"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>